NCT00362323已完成3 期
A Randomized, Double-blind Study Comparing the Efficacy and Safety of a Fixed Combination of Fenofibrate and Metformin vs Metformin Alone in Patients With Type 2 Diabetes Mellitus and Dyslipidemia Not Appropriately Controlled With a Statin.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 482
- 试验地点
- 70
- 主要终点
- TG / HDL-C ratio
研究概览
简要总结
To demonstrate in patients with T2DM and dyslipidemia not appropriately controlled with a statin and receiving metformin, the superiority of a fixed combination of fenofibrate and metformin vs metformin alone on TG and additionally, if the superiority on TG is established, to demonstrate the superiority on HDL-C
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
1
Experimental
干预措施: fenofibrate (F) + metformin (M) hydrochloride fixed combination (Drug)
2
Active Comparator
干预措施: Metformin (Drug)
结局指标
主要结局
TG / HDL-C ratio
时间窗: 24 weeks
次要结局
- Lipid and glycemic parameters(24 weeks)
研究者
研究点 (70)
Loading locations...
相似试验
已完成
3 期
A Controlled-Study of Fenofibrate 145 mg and Ezetimibe 10 mg in Type IIb Dyslipidemic Patients With Features of the Metabolic SyndromeHyperlipidemia CombinedNCT00349284Solvay Pharmaceuticals181
进行中（未招募）
2 期
A Study in Patients With Mixed DyslipidemiaMixed DyslipidemiaNCT06497127Shanghai Argo Biopharmaceutical Co., Ltd.145
已完成
3 期
Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and DyslipidemiaHypertensionDyslipidemiaNCT01402843JW Pharmaceutical150
已完成
2 期
Study In Patients With DyslipidaemiaMetabolic Syndrome XNCT00264667GlaxoSmithKline290
已完成
3 期
A Study In Patients With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT00256867GlaxoSmithKline369